NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Alector, Inc. ALEC
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$21.0M
▼ 79.1% vs FY2024
EPS · FY25
$-1.39
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-181.6%
Net margin · FY25
-679.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 21.0M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 679 cents on every revenue dollar this year.
Per share
USD -1.39
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-181.6%
Return on equity, FY2025
ROE
Operating margin-741.3%
Net margin-679.2%
Return on assets-37.5%
Each USD of equity lost 182 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−0.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−46.0%
−0.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+39.1%
Change, 10 years—
The share count grew 39% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 293.2M
total assets, end of FY2025
Total assetsUSD 293.2M
EquityUSD 30.6M
CashUSD 65.8M
Gross debtUSD 9.7M
Net debtUSD -56.1M
Current ratio3.83×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.1
0.1
0.1
0.2
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.1
−0.2
−0.1
−0.0
−0.2
−0.1
−0.1
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.2
−0.1
−0.1
−0.0
EPS, diluted $
−1.39
−1.23
−1.56
−1.62
−0.45
−2.45
−1.71
−4.62
−3.55
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−181.6
−91.2
−74.8
−51.8
−12.8
−82.3
−216.5
·
·
Shares out B
0.11
0.10
0.08
0.08
0.08
0.08
0.07
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed